DXCM
Dexcom Inc.
Is DXCM Halal?
Continuous glucose-monitoring devices serve a generally permissible, life-preserving medical purpose, while March 2026 identifiable liquidity exceeds the examined one-third limit.
What You Should Know
Dexcom develops continuous glucose-monitoring systems for diabetes care; preserving life and health (hifz al-nafs) supports the existing qualitative assessment. Its March 31, 2026 filing shows debt at 18.72% of total assets and receivables plus cash at 33.27%, while cash plus short-term marketable debt securities is 36.41%. The filing reports other income net and does not provide a standalone gross interest-income numerator, so no unsupported purification percentage is prescribed.
⚠️ Concerns
- •Cash plus short-term marketable debt securities were 36.41% of total assets at March 31, 2026
- •Debt was 18.72% of total assets
- •Other income includes interest and dividend income but does not isolate a gross non-compliant-income amount
- •Device safety, accuracy, patient access, reimbursement, privacy, manufacturing, labor and electronic-waste impacts require qualitative review
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-14.
1,242 / 6,633
2,415 / 6,633
2,207 / 6,633
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 36.41%, above the examined 33.333% limit; debt/assets is 18.72% and receivables plus cash/assets is 33.27%. Gross interest income is unavailable.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 36.41%, above the examined 33.33% total-assets limit; debt and receivables plus cash pass. This is not an index-membership claim.
- Financial
- Fails
- Overall
- Fails
Identifiable liquidity/assets is 36.41%, above the examined 33% financial limit; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Dexcom develops continuous glucose-monitoring systems and related software and services for diabetes care. Medical devices that support health and preserve life are generally permissible.
Limitation: The filing does not classify every product input, customer, reimbursement channel or downstream use; no unsupported prohibited-revenue estimate is made.
Purification
Other income includes interest and dividend income but does not provide a standalone gross non-compliant-income numerator; no fixed purification percentage is prescribed.
Inputs, assumptions and primary sources
- Amounts are USD millions from Dexcom's March 31, 2026 Form 10-Q and rounded to the nearest million.
- Interest-bearing debt is the $1,242 million carrying value of long-term senior convertible notes; operating lease liabilities are excluded.
- Cash is $1,118 million and short-term marketable securities are $1,297 million of available-for-sale debt securities.
- Net accounts receivable is $1,089 million and quarterly revenue is $1,192 million.
- Dexcom reports other income, net of $14 million and explains that it includes interest and dividend income, but does not isolate gross interest income; the income screen is therefore unavailable.
- Dexcom's disclosed business is glucose-monitoring devices and related services; no prohibited operating category is identified in the filing, while product-level ingredients and downstream use remain qualitative.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →